Programmed cell death ligand 1 expression associated with subtypes of post‐transplant lymphoproliferative disorder among pediatric kidney transplant recipients
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Olga K Weinberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Epstein-Barr Virus Infections, Lymphoproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Programmed cell death ligand 1 (PD‐L1) expression on tumor cells engages the PD‐1 receptor on T cells, inhibiting anti‐tumor responses. PD‐L1 has been detected in cases of post‐transplant lymphoproliferative disorder (PTLD) but reports are limited. Here we examine PD‐L1 expression and evaluate for clinical correlations.
Methods
Twenty‐one cases of PTLD were identified among pediatric kidney transplant recipients at our institution from February 1996 to April 2017. Using paraffin‐embedded tissue biopsies, we examined 21 primary tumors for expression using PD‐L1 monoclonal antibody performed with PAX5 as a double stain. We scored expression of PD‐L1 on lesional B‐cells as a percentage of positive cells. Clinical course and outcome were obtained from retrospective chart review.
Results
Applying revised 2017 WHO PTLD classification showed five non‐destructive, nine polymorphic, and seven monomorphic cases. Average PD‐L1 expression based upon PTLD subtype was: non‐destructive 11%, polymorphic 43%, and monomorphic 73% ( p = .01). Two patients transferred shortly after diagnosis, five received chemotherapy, and three died from PTLD. Among the fatalities, all showed monomorphic PTLD and 90% of lesional B‐cells expressed PD‐L1.
Conclusion
In this case series, significant differences in PD‐L1 expression were seen among different subtypes, and monomorphic PTLD demonstrated the highest expression. Study of a larger cohort is needed, and if the correlation of PD‐L1 expression and PTLD subtype is confirmed, this may highlight the potential utility of checkpoint inhibitor therapy in cases of severe or refractory disease among kidney transplant recipient in whom the risk of allograft loss is acceptable given the option of chronic dialysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Nephrology and Hypertension, Rabin Medical Center, Petah Tikva, Israel.
- Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Timna Agur, Nancy M Rodig
Zitieren
APA
Weinberg, O. K., Pinkus, G. C., Ramos-Gonzalez, G. J., Agur, T., & Rodig, N. M. (2023). Programmed cell death ligand 1 expression associated with subtypes of post‐transplant lymphoproliferative disorder among pediatric kidney transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15134
Vancouver
Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM. Programmed cell death ligand 1 expression associated with subtypes of post‐transplant lymphoproliferative disorder among pediatric kidney transplant recipients. Clinical Transplantation. 2023. doi:10.1111/ctr.15134
BibTeX
@article{Weinberg2023,
author = {Weinberg, Olga K and Pinkus, Geraldine C and Ramos-Gonzalez, Gabriel J and Agur, Timna and Rodig, Nancy M},
title = {Programmed cell death ligand 1 expression associated with subtypes of post‐transplant lymphoproliferative disorder among pediatric kidney transplant recipients},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15134}
}
EUVIMED